Gebasaxturev
Vaccineexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 16, 2019 (NCT04152863)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095439 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04521621 | Phase 1/Phase 2 (Phase 2) | Oct 28, 2020 | Merck |
| NCT04303169 | Phase 1/Phase 2 (Phase 2) | Jul 3, 2020 | Merck |
| NCT04152863 | Phase 2 | Dec 16, 2019 | Merck |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 3 | 3 | 1 | 2019 |
1 organizations
Page 1 / 1